Acetylation genotype and the genetic susceptibility to prostate cancer in a southern European population

被引:29
作者
Costa, I
Pinto, D
Morais, A
Vasconcelos, A
Oliveira, J
Lopes, C
Medeiros, R
机构
[1] Univ Minho, ICVS, Sch Hlth Sci, Life & Hlth Sci Res Inst, P-4710057 Braga, Portugal
[2] Inst Portugues Oncol Francisco Gentil, Dept Pathol, Oporto, Portugal
[3] Inst Portugues Oncol Francisco Gentil, Dept Urol, Oporto, Portugal
[4] Abel Salazar Inst Biomed Sci, ICBAS, Oporto, Portugal
关键词
NAT; polymorphisms; prostate cancer; acetylation; heterocyclic aromatic amines;
D O I
10.1002/pros.20241
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. Epidemiologic studies have suggested that environmental factors and diet are important risk factors in the pathogenesis of prostate cancer. The N-acetyltransferases (NAT) are important enzymes in activation and inactivation of various carcinogens, including those found in well-cooked meat and cigarette smoke. METHODS. We analyzed DNA samples from 146 prostate cancer patients and 174 healthy men. We used PCR-RFLP method to analyze NAT1 and NAT2 polymorphisms. RESULTS. We did not find statistically significant differences in NATI genotypes frequencies between prostate cancer patients and control group. We observed an association of the slow acetylator genotype, NAT2*6/NAT2*6 with prostate cancer protection (P = 0.017; OR = 0,31, 95%(CI 0.11-0.84). Multivariate logistic regression analysis confirmed this association (0.030; OR = 0.32,95% CI 0.12-0.89). CONCLUSIONS. Our results indicate a role of NAT2 polymorphisms in the carcinogenic pathway of prostate cancer, specifically in a population of Southern Europe. (c) 2005 Wiley-Liss, Inc.
引用
收藏
页码:246 / 252
页数:7
相关论文
共 36 条
[1]  
BELL DA, 1995, CANCER RES, V55, P5226
[2]   HUMAN ARYLAMINE N-ACETYLTRANSFERASE GENES - ISOLATION, CHROMOSOMAL LOCALIZATION, AND FUNCTIONAL EXPRESSION [J].
BLUM, M ;
GRANT, DM ;
MCBRIDE, W ;
HEIM, M ;
MEYER, UA .
DNA AND CELL BIOLOGY, 1990, 9 (03) :193-203
[3]  
Brockton N, 2000, AM J EPIDEMIOL, V151, P846
[4]   Pharmacogenetics of the arylamine N-acetyltransferases [J].
Butcher N.J. ;
Boukouvala S. ;
Sim E. ;
Minchin R.F. .
The Pharmacogenomics Journal, 2002, 2 (1) :30-42
[5]  
CASCORBI I, 1995, AM J HUM GENET, V57, P581
[6]   A slow acetylator genotype associated with an increased risk of advanced cervical cancer [J].
Costa, S ;
Medeiros, R ;
Vasconcelos, A ;
Pinto, D ;
Lopes, C .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2002, 128 (12) :678-682
[7]   Association between CYP2E1 polymorphisms and susceptibility to prostate cancer [J].
Ferreira, PM ;
Medeiros, R ;
Vasconcelos, A ;
Costa, S ;
Pinto, D ;
Morais, A ;
Oliveira, J ;
Lopes, C .
EUROPEAN JOURNAL OF CANCER PREVENTION, 2003, 12 (03) :205-211
[8]   N-acetyltransferase 1 genetic polymorphism influences the risk of prostate cancer development [J].
Fukutome, K ;
Watanabe, M ;
Shiraishi, T ;
Murata, M ;
Uemura, H ;
Kubota, Y ;
Kawamura, J ;
Ito, H ;
Yatani, R .
CANCER LETTERS, 1999, 136 (01) :83-87
[9]  
Garte S, 2001, CANCER EPIDEM BIOMAR, V10, P1239
[10]   Genetic polymorphism of N-acetyltransferase-2, glutathione S-transferase-M1, and cytochromes P450IIE1 and P450IID6 in the susceptibility to head and neck cancer [J].
González, MV ;
Alvarez, V ;
Pello, MF ;
Menéndez, MJ ;
Suarez, C ;
Coto, E .
JOURNAL OF CLINICAL PATHOLOGY, 1998, 51 (04) :294-298